PCOS is often described as a hormonal condition, but the deeper driver in most cases is metabolic — specifically, insulin resistance. Diamanti-Kandarakis (Endocr Rev 2012) summarized the mechanism: insulin acts as a co-gonadotropin in the ovary, amplifying androgen production and disrupting follicular development, while in the liver it suppresses sex hormone-binding globulin (SHBG), raising the bioavailable fraction of testosterone. This is why a single metabolic problem — insulin not working as well as it should — produces the cycle, hair, skin, and fertility symptoms women with PCOS experience.
This post explains what insulin resistance is, why it matters in PCOS, how it is measured, and what the evidence shows for the main interventions.
What insulin resistance actually is
Insulin’s job is to move glucose from blood into cells (especially muscle and liver) for energy or storage. In insulin resistance, cells respond less to insulin’s signal, so the pancreas compensates by producing more. The blood glucose level may stay normal for years while insulin levels climb.
Eventually, if the pancreas cannot keep up, fasting glucose rises and type 2 diabetes develops. Long before that point, the high-insulin state alone has effects elsewhere in the body — and the ovary is one of the most sensitive tissues.
How insulin drives PCOS symptoms
Three main pathways explain why insulin resistance shows up as PCOS symptoms:
1. Direct ovarian androgen production
Theca cells in the ovary have insulin receptors. High insulin levels stimulate these cells to produce more androgens (testosterone, androstenedione). This is not a failure of regulation; it is a normal response to abnormally high insulin signals.
2. Suppressed SHBG
The liver makes sex hormone-binding globulin, which binds testosterone in the blood and reduces the free, biologically active fraction. Insulin suppresses SHBG production. Lower SHBG plus higher total testosterone produces a much higher free testosterone — the hormone fraction that actually reaches androgen-sensitive tissues like skin and hair follicles.
3. LH amplification
Insulin amplifies pituitary LH secretion and theca cell sensitivity to LH. The result is a cycle where the LH-to-FSH ratio is shifted toward LH dominance, contributing to the characteristic follicular arrest seen on ultrasound (the “polycystic” appearance).
The clinical picture: irregular cycles, anovulation, hirsutism, acne, scalp hair thinning, sometimes acanthosis nigricans (velvety dark skin in the neck or armpits, a clinical sign of insulin resistance).
For the diagnostic framework, see PCOS Rotterdam criteria explained.
How is insulin resistance measured?
The gold standard is the hyperinsulinemic-euglycemic clamp, which is research-only.
In clinical practice, surrogates are used:
- HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) = (fasting glucose mg/dL x fasting insulin mIU/L) / 405. Values above 2.5 are commonly considered suggestive of insulin resistance, though precise cutoffs vary by lab and population.
- Fasting insulin alone. Levels above 10 to 12 mIU/L are often interpreted as suggestive, though insulin assays vary widely.
- 2-hour 75g oral glucose tolerance test (OGTT) with both glucose and insulin measured. Catches early glucose intolerance and identifies people whose post-load insulin levels are very high even when glucose looks normal.
- A1C. Reflects 3-month average glucose. Useful but less sensitive to early insulin resistance.
The 2018 international PCOS guideline recommends OGTT (rather than just fasting glucose or A1C) for women with PCOS who have BMI 25 or higher, family history of type 2 diabetes, age over 40, or prior gestational diabetes, with repeat testing every 1 to 3 years.
Why this matters even if you are not “overweight”
Lean PCOS exists. Roughly 30 percent of women with PCOS have BMI under 25, and a substantial portion of these still have measurable insulin resistance. Body composition (visceral fat, low muscle mass) and genetics both matter independently of BMI.
This is why the 2018 guideline explicitly recommends OGTT screening for PCOS regardless of weight, and why interventions targeting insulin sensitivity (movement, sleep, dietary modifications) help even women who do not need to lose weight.
For more on BMI’s limitations, see BMI vs body fat percentage and waist-to-height ratio.
What helps: lifestyle interventions
Lifestyle change is the foundation. Even modest improvements move the needle:
Movement
Resistance training and aerobic exercise both improve insulin sensitivity. Resistance training adds muscle mass, which is the largest insulin-sensitive tissue in the body. The 2018 PCOS guideline recommends 150 minutes of moderate or 75 minutes of vigorous activity weekly, plus 2 sessions of resistance training.
Diet
No single diet has been proven superior for PCOS. What does have evidence:
- Modest carbohydrate moderation (especially refined carbs and added sugars), not extreme restriction.
- Protein at every meal to support muscle and satiety.
- Fiber from vegetables, legumes, whole grains, fruit. Improves both insulin sensitivity and the gut microbiome.
- Mediterranean pattern has the most population-level evidence for metabolic health.
Crash diets and very-low-calorie approaches generally make hormones worse for women with PCOS, not better.
Weight management when relevant
A 5 to 10 percent reduction in body weight has been shown to restore ovulation in a substantial fraction of women with PCOS who are overweight. Weight gain is not a moral failing — PCOS itself makes weight gain easier and weight loss harder due to the underlying insulin biology — but when it is achievable, the metabolic and cycle benefits are large.
Sleep
Sleep deprivation worsens insulin resistance acutely. Treating obstructive sleep apnea (which is more common in PCOS even at lower BMI) and protecting consistent sleep schedules both help.
What helps: medications
Metformin
Metformin lowers hepatic glucose production and improves peripheral insulin sensitivity. In PCOS:
- Cycle regularity: modest improvement in many women, especially with BMI 25 or higher.
- Ovulation induction: less effective than letrozole alone, but combination metformin plus letrozole has support in selected patients.
- Type 2 diabetes prevention: clear benefit in those with impaired glucose tolerance.
- Weight: modest weight reduction in many women, larger in those with significant hyperinsulinemia.
Common dose 1,500 to 2,000 mg/day, divided. GI side effects (nausea, loose stools) are common initially and usually settle within 2 to 4 weeks. Extended-release formulations are better tolerated.
Inositols
Myo-inositol with d-chiro-inositol (40:1 ratio) has shown improvements in cycle regularity and ovulation in several trials, though the evidence base is weaker than metformin. Many endocrinologists consider inositols a reasonable option, particularly for women who do not tolerate metformin.
Combined oral contraceptives
These do not treat insulin resistance. They are first-line for cycle regulation, hirsutism, and acne management because they suppress ovarian androgen production and increase SHBG. They are often used together with metformin for women who need both cycle suppression and metabolic benefit.
GLP-1 agonists
Newer medications (semaglutide, liraglutide) improve insulin sensitivity and produce meaningful weight loss in many people, including women with PCOS. They are not yet standard PCOS therapy but are being studied. Pregnancy is a contraindication, so timing matters.
Where this fits with fertility
Insulin resistance is a major driver of anovulation in PCOS. Treating it (lifestyle plus metformin where indicated) can restore ovulation in many women without needing additional fertility medications. When ovulation induction is needed, letrozole is first-line. See PCOS and fertility for the full fertility-focused walkthrough.
If your cycles are irregular, the Period Calculator helps you log patterns to share with your clinician. The BMI Calculator gives one data point; pair it with waist circumference for a fuller metabolic picture.
Questions worth asking
- Have I had an OGTT (not just fasting glucose) recently?
- What is my fasting insulin and HOMA-IR?
- Do I meet criteria for metformin under the 2018 PCOS guideline?
- What is my A1C and how does it compare to a year ago?
- Are there sleep, mood, or stress factors making this worse?
The bottom line
Insulin resistance underlies a large fraction of PCOS cases regardless of BMI. It drives hyperandrogenism through direct ovarian effects, SHBG suppression, and LH amplification. Diagnosis is clinical plus surrogates (HOMA-IR, OGTT). The first-line interventions are movement, nutrition, and sleep, with metformin or inositols added when indicated. Targeting the metabolic root cause produces the broadest improvement across cycles, skin, hair, fertility, and long-term disease risk.